Akrotome Imaging

Akrotome Imaging is a private U.S. medical imaging and diagnostics company developing fluorescent molecular probe technologies to improve cancer surgery. Its patented FIRE (Fluorescent Image Resection Enhancement) platform is designed to help surgeons distinguish tumor tissue from healthy tissue in real time during operations, with an initial focus on intraoperative tumor-margin assessment. The company’s lead probe, 6qcICG, is a quenched, activity-based probe targeting activated cysteine cathepsins associated with many solid tumors. Akrotome is positioning the technology for guided surgery and related diagnostic applications, particularly in breast-conserving surgery and non-melanoma skin cancer, with future potential in additional solid tumors. The company appears to be private, grant-backed, and in clinical translation rather than commercial-stage operations.